Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts

To explore mechanisms by which SGLT2 inhibitors protect diabetic hearts from heart failure, we examined the effect of empagliflozin (Empa) on the ultrastructure of cardiomyocytes in the noninfarcted region of the diabetic heart after myocardial infarction (MI). OLETF, a rat model of type 2 diabetes,...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Physiol Rep
Päätekijät: Mizuno, Masashi, Kuno, Atsushi, Yano, Toshiyuki, Miki, Takayuki, Oshima, Hiroto, Sato, Tatsuya, Nakata, Kei, Kimura, Yukishige, Tanno, Masaya, Miura, Tetsuji
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2018
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6014462/
https://ncbi.nlm.nih.gov/pubmed/29932506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14814/phy2.13741
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia